Browse

Current Perspectives on Therapeutic Antibodies

Cited 18 time in Web of Science Cited 16 time in Scopus
Authors
Yoon, Soomin; Kim, Yong-Sung; Shim, Hyunbo; Chung, Junho
Issue Date
2010-10
Publisher
KOREAN SOC BIOTECHNOLOGY & BIOENGINEERING
Citation
BIOTECHNOLOGY AND BIOPROCESS ENGINEERING; Vol.15 5; 709-715
Keywords
efficacyimmunogenicitytherapeutic monoclonal antibodyserum half-life
Abstract
Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy.
ISSN
1226-8372
Language
English
URI
http://hdl.handle.net/10371/76844
DOI
https://doi.org/10.1007/s12257-009-3113-1
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Biochemistry & Molecular Biology (생화학교실)Journal Papers (저널논문_생화학교실)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse